# Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
Canonical URL: https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-recent-progress
Ticker: RCKT
Company: Rocket Pharmaceuticals
Source: Rocket Pharmaceuticals
Published: 2026-02-26 21:00 EST
Original Source URL: https://ir.rocketpharma.com
## Summary

Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026 KRESLADI ™ for severe LAD-I on track for March 28, 2026 PDUFA date Dosing of first patient in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026 Cash, cash equivalents and investments of

## Article Body
Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026 KRESLADI ™ for severe LAD-I on track for March 28, 2026 PDUFA date Dosing of first patient in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026 Cash, cash equivalents and investments of
## Recent Company News
- 2026-05-07 20:00 EST — [Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-reports-first-quarter-2026-financial-results-and-highlights-recent-progress) — Source: Rocket Pharmaceuticals
- 2026-04-28 11:00 EST — [Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-announces-180-million-sale-of-priority-review-voucher) — Source: Rocket Pharmaceuticals
- 2026-03-27 11:00 EST — [Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-announces-fda-approval-of-kresladitm-for-pediatric-patients-with-severe-leukocyte-adhesion-deficiency-i-lad-i) — Source: Rocket Pharmaceuticals
- 2026-02-26 21:00 EST — [Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-recent-progress) — Source: Rocket Pharmaceuticals
- 2026-02-23 12:00 EST — [Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RCKT/rocket-pharmaceuticals-to-participate-in-upcoming-investor-conferences) — Source: Rocket Pharmaceuticals
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)